NeoMatrix Therapeutics, Inc. (NMT) was founded by Richard A. Clark, M.D., Professor of Dermatology, Biomedical Engineering, and Medicine at Stony Brook University.

​

After years of investigating why wounds fail to heal, Dr. Clark and Dr. Lin discovered cell-survival peptides in the extracellular matrix that are absent in nonhealing wounds and burns. These peptides, NMT-cP12 and NMT-cNP8, promote tissue cell survival and growth under harsh culture conditions that mimic unfavorable wound conditions. We also found that intravenous (IV) NMT-cP12 at 2-8 hours and IV NMT-cNP8 at 8 to 24h post-burn shortened healing time in a porcine burn model burn. Furthermore, we found that NMT-cNP8 is an anti-microbial peptide that is under development for topical use.

​

The US Army began funding the development of NMT-cP12 in 2012 and NMT-cNP8 in 2015 and has continued development of these peptides since that time.  Both peptides have completed IV Phase 1 Clinicals Trials and IV cP12 Phase 2a is to be launched, May, 2025.

​

NMT is headquartered in the Long Island High Tech Incubator on the campus of Stony Brook University.